Patients & Advocacy
We are fueled by a strong commitment to patients
Driven by a sense of urgency to address long-standing lack of innovation, GBT is changing the way treatments are developed and delivered. We are collaborating with the sickle cell community, including healthcare professionals, patient advocacy groups and community-based organizations, to increase awareness of sickle cell disease (SCD) and how it affects patients. We are working to change the treatment paradigm in this disease, while helping the sickle cell community advocate for quality care.
We understand that removing barriers to care is critical
GBT is committed to helping people with SCD gain broad access to our therapies, once approved by regulatory authorities, and to remove other barriers to care. We do this, in part, by working with government agencies, including the U.S. Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS), and policymakers to develop breakthroughs in SCD treatment and enable broader access to care. We also provide funding support for the U.S. Centers for Disease Control and Prevention’s Sickle Cell Data Collection Program, which collects health information about people with SCD to study long-term trends in diagnosis, treatment and access to healthcare.
GBT supports the efforts of community-based patient advocacy organizations to improve the lives of all people living with SCD. We applaud Sick Cells and 46 members of the SCD community for their March 18, 2021 letter to the Biden Administration outlining key policy priorities to create positive change for the community.